Immunogenicity and Safety of Concomitant Administration of Bivalent COVID-19 Vaccines With Influenza Vaccines
Key facts
- Who runs it
- Catholic Kwandong University
- Where
- South Korea1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- Phase
- Phase 4
- People taking part
- 154 people enrolled
- Started
- 12 Oct 2022
- Ended
- 15 Dec 2023
- Type of study
- Interventional, 3 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
- quadrivalent influenza vaccine
- Record updated
- 26 March 2024
Who can take part
- Age
- 18 years to 65 years
- Sex
- Women and men
- Healthy volunteers
- Can take part
The registry criteria, word for word
Show all 3 criteriaShow less
Who can take part
- who agreed to receive both bivalent booster COVID-19 vaccine and influenza vaccine
- Only individuals who had passed at least 3 months after the last confirmation of SARS-CoV-2 infection and/or the third dose of COVID-19 vaccination
Who cannot take part
- Individuals with a contraindication to any of the vaccine compounds were excluded from the study
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The goal is to evaluate the immunogenicity and safety of coadministration of a bivalent BA.4/BA.5-adapted COVID-19 booster vaccine, and influenza vaccine among healthy adults during 2022-23 season.
The 3 groups in the trial
- C groupTreatment being tested
Concomitant administration of bivalent mRNA COVID-19 booster and quadrivalent influenza vaccination
Treatment: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine and quadrivalent influenza vaccine
- S group (COVID-19 vaccine only)Placebo, for comparison
separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
Treatment: bivalent BNT162b2 mRNA original/omicron BA.4-5 vaccine
- S group (influenza vaccine only)Placebo, for comparison
separate administration of influenza vaccination followed by bivalent BA.4/BA.5 mRNA booster ≥4 weeks later
Treatment: quadrivalent influenza vaccine
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Immunogenicity and Safety of Concomitant Administration of Omicron-containing Bivalent COVID-19 Vaccines With Seasonal Influenza Vaccines
- Record updated
- 26 March 2024